BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company’s primary commercial product is ORLADEYO (berotralstat), an oral, once-daily therapy approved in the United States and multiple global markets for the prevention of HAE attacks in adults and pediatric patients. BioCryst also markets RAPIVAB, RAPIACTA, and PERAMIFLU (peramivir injection), intravenous neuraminidase inhibitors for the treatment of acute uncomplicated influenza in the United States, Australia, Canada, Japan, Taiwan, and Korea. The company’s pipeline includes Navenibart (STAR-0215), a monoclonal antibody for HAE in Phase 3, and BCX17725, a protein therapeutic for Netherton Syndrome in Phase 1. Additional candidates in development include Avoralstat for diabetic macular edema and STAR-0310 for atopic dermatitis. BioCryst utilizes structure-guided drug design technologies to develop oral small-molecule and injectable protein therapeutics. The company maintains commercial infrastructure in the United States and partners with licensing and distribution partners in Japan, the pan-Latin America region, and parts of Europe and Asia. Founded in 1986, BioCryst operates as a commercial-stage biotech with a focus on rare disease markets.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage biocryst.com
Sector Healthcare IR page ir.biocryst.com
Tags
hereditary angioedema, rare diseases, oral small-molecule therapeutics, injectable protein therapeutics, influenza treatment, structure-guided drug design, kallikrein inhibitors, neuraminidase inhibitors, specialty pharmacy, clinical development, ORLADEYO, berotralstat, Navenibart, STAR-0215, BCX17725, Avoralstat, STAR-0310, RAPIVAB, peramivir, RAPIACTA, PERAMIFLU, EMPOWER Patient Services
Press page —

Metrics

Valuation  
Market cap $ 2.133B
Market cap (USD) $ 2.133B
P/E -5.91
PEG —
P/BV -5.37
P/S 2.22
P/OCF 5.81
P/FCF 5.83
Dividend yield —
Turnover / mcap —
Returns  
ROE -221.4%
ROI —
ROIC —
Profit margin 30.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 55
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Revenue 874.837M 450.712M 331.412M 270.827M 157.17M 17.812M 48.835M 20.653M 25.186M 26.353M 48.257M 13.608M 17.331M 26.293M 19.643M 62.381M 74.589M — — — — — 1.634M 1.775M 11.158M 7.661M 5.329M 7.626M
Net profit 263.861M -88.881M -226.539M -247.116M -184.062M -182.814M -108.897M -101.252M -65.782M -55.144M -43.019M -45.189M -30.108M -39.081M -56.948M -33.853M -13.452M -24.732M -29.056M -43.618M -26.099M -21.104M -12.7M -16.929M -4.986M -11.578M -5.298M -4.785M
Free cash flow 344.901M -53.144M -97.309M -163.201M -144.542M -137.73M -89.927M -92.931M -41.471M -58.715M -18.238M -38.657M -26.56M -37.51M -32.306M -28.88M -16.822M -22.086M -28.342M -16.61M -23.843M -18.427M -11.248M -16.772M -12.763M -5.901M -5.815M -4.562M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Share price 7.8 7.52 5.99 11.48 13.85 7.45 3.45 8.07 4.91 6.33 10.32 12.16 7.6 1.43 2.45 6.2 6.47 1.48 12 10.21 — — — — — 9 — —
Price performance 12m 0.04 0.26 -0.48 -0.17 0.86 1.16 -0.57 0.64 -0.22 -0.39 -0.15 0.6 4.32 -0.42 -0.6 -0.04 3.37 -0.88 0.18 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 8.77M 6.12M 4.29M 22.1M 8.65M 29.4M 50.6M 57M 79.1M 107M
↳ YoY growth +40.4% -30.2% -29.8% +415.9% -61.0% +240.2% +72.0% +12.6% +38.8% +35.1%
↳ 5y CAGR +8.5% +6.0% +15.2% +41.9% +6.7% +27.4% +52.6% +67.7% +29.0% +65.3%
Borrowings, non-current (USD) — — — 0.00 120M 136M 232M 303M 315M 0.00
Lease liabilities (USD) — — 2.75M 4.78M 5.05M 7.78M 8.17M 13.9M 12.8M 11.6M
Cash and deposits (USD) 22.1M 50.3M 26.7M 114M 272M 504M 305M 111M 105M 89.7M
Right-of-use assets (USD) — — — — — 6.47M 6.81M 8.68M 8.06M 7.55M
Net debt (borrowings + leases - cash) (USD) — — — -109M -147M -361M -65M 206M 223M -78.1M
Cash flow detail
Operating cash flow (USD) -53.4M -41.1M -92.6M -89.6M -137M -142M -162M -95.1M -52M 347M
Purchases of property, plant and equipment (USD) -5.28M -328,000 -366,000 -343,000 -514,000 -2.39M -1.35M -2.17M -1.12M -2.47M
Change in receivables (cash effect) (USD) -2.53M 2.65M 1.82M -17.9M 13.9M -20.8M -21.5M -6.1M -22.7M -36.8M
Change in inventories (cash effect) (USD) 1.11M 500,000 -1.65M 1.65M -7.04M -8.77M -12.4M -1.45M -4.16M -1.64M
Change in payables (cash effect) (USD) -10.5M 3.84M 4.49M 11.7M 17.4M 39.4M -22.4M -16.8M -62.4M 57.8M
Interest paid (cash effect) (USD) — — — — — -900,000 0.00 -22.1M -30.4M -23.7M
Income taxes paid (cash effect) (USD) — — — — — -118,000 -3.54M -1.43M -1.6M -2.8M
Share-based compensation (USD) 8.49M 12.6M 9.4M 17.7M 14.8M 34.6M 44.7M 55.6M 65.4M 85.1M
Operating cash flow before change in receivables (USD) -50.9M -43.8M -94.4M -71.7M -151M -121M -140M -89M -29.3M 384M
Free cash flow (OCF - PPE - intangibles) (USD) -58.7M -41.5M -92.9M -89.9M -138M -145M -163M -97.3M -53.1M 345M
Income detail
Research and development expense (USD) 61M 67M 84.9M 107M 123M 209M 253M 217M 175M 166M
↳ 5y CAGR +1.4% +5.4% +14.7% +15.6% +11.1% +27.9% +30.5% +20.6% +10.3% +6.2%
Total comprehensive income (USD) -55M -66M -101M -109M -183M -184M -247M -225M -89.3M 263M
Comprehensive income to owners (USD) -55M -66M -101M -109M -183M -184M -247M -225M -89.3M 263M
Reported Feb 27, 2017 Mar 12, 2018 Mar 13, 2020 Mar 1, 2021 Mar 1, 2021 Feb 27, 2024 Feb 27, 2024 Feb 27, 2024 Feb 25, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026

PDF Version

— Total net revenue of $180.3 million and ORLADEYO®net revenue of $174.8 million —

— Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million —

— Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million —

— Improved Non-GAAP operating expense guidance to $415 to $425 million —

— Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older —

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended September 30, 2026, and provided a business update.

"In the third quarter, we delivered continued growth of ORLADEYO and strong profitability while broadening the foundation for our long-term success," said Charlie Gayer, President and Chief Executive Officer of BioCryst. “We successfully launched ORLADEYO pellets in pediatric patients, received FDA approval for their use in adolescents and adults in October, and implemented our specialty pharmacy transition to CareMed, all of which will make ORLADEYO accessible for more patients. Looking to our pipeline, BCX17725 remains on track for the early clinical data by the end of this year, and we look forward to navenibart pivotal results in the third quarter of 2027. This progress across our business increases our confidence in our ability to drive sustainable growth and lasting value for patients and shareholders."

Business & Corporate Updates

  • The launch of ORLADEYO oral pellets in patients with hereditary angioedema (HAE) aged 2 to <12 years began in August. Early reimbursement is strong and new prescriptions continue to be filled ahead of the company’s expectations.

  • In October, the FDA approved the company’s supplemental New Drug Application for the use of the oral pellet formulation of once-daily ORLADEYO for patients with HAE aged 12 years and older. This approval enables prescribers to offer their patients a more personalized treatment choice with ORLADEYO in either capsule or pellet form.

  • In August, the company commenced operations with CareMed as its sole-source specialty pharmacy partner for ORLADEYO shipments to patients. CareMed’s deep rare disease experience, high-touch patient services, and operational scale make it a strong partner to drive continued growth of ORLADEYO across patient segments and formulations.

  • The company is studying navenibart, an investigational, long-acting plasma kallikrein inhibitor, in ALPHA-ORBIT, the ongoing and fully enrolled pivotal study in hereditary angioedema with every three-month and every six-month subcutaneous dosing, and ORBIT-EXPANSE, the long-term extension study. The program remains on track to report top-line results at six- and twelve-month endpoints in Q3 2027.

  • The company is studying BCX17725, an investigational KLK5 inhibitor for the treatment of Netherton syndrome (NS), in a Phase 1 trial. The company has enrolled Part 4 of this trial and expects to report initial data in patients with NS by the end of 2026.

  • The company's Birmingham site closure activities are on track to be substantially complete by year-end. The company expects the site closure and associated restructuring to result in cash costs of approximately $10 million total and annualized cost savings of approximately $30 million to $35 million once fully realized, not including additional savings from other program-related expenses.

  • In October, the company announced the formation of a Scientific Advisory Board comprising seven accomplished scientific and industry leaders to provide independent guidance and expertise for the successful execution of the external R&D strategy.

  • The company has discontinued development of STAR-0310, the early-stage atopic dermatitis program acquired through the acquisition of Astria Therapeutics, to focus resources on rare diseases. The company previously paused investment in the program while it explored partnering opportunities, and it has now concluded that effort.

Third Quarter 2026 Financial Results

Total revenues were $180.3 million (+13% y-o-y; +24% y-o-y on a comparable basis excluding European revenue). Revenue growth in the quarter benefited from the transition to CareMed as the company's sole-source specialty pharmacy partner for shipments to patients. As part of its distribution model, CareMed built an initial inventory of ORLADEYO to support patient demand and efficient dispensing, consistent with customary specialty pharmacy practices. The company expects that inventory level to remain relatively stable over time. ORLADEYO revenue, excluding European revenue, grew year-over-year when removing the effect of the initial inventory build.

Research and development expenses, excluding stock-based compensation expense, were $52.4 million for the third quarter of 2026. Research and development expenses for the quarter include one-time impairment charges associated with the closure of the Birmingham site and employee termination costs. Total restructuring costs in research and development included cash costs of $6.3 million and non-cash costs of $9.3 million.

  • On a non-GAAP basis, R&D expenses were $37.1 million for the third quarter of 2026, compared to $38.0 million for the third quarter of 2025. While costs increased due to navenibart pivotal program, overall expenses decreased due to lower expenses related to BCX17725 and the termination of programs related to the Birmingham facility closure.

Sales and marketing expenses, excluding stock-based compensation expense, were $37.7 million (-15% y-o-y) on a GAAP basis and $36.0 million (+4% y-o-y) on a non-GAAP basis. Fees related to the specialty pharmacy transition contributed to the increase. General and administrative expenses, excluding stock-based compensation expense, were $21.0 million (-22% y-o-y) on a GAAP basis and $19.1 million (-8% y-o-y) on a non-GAAP basis.

The company recorded an operating profit of $53.3 million for the third quarter of 2026 compared to $29.6 million for the third quarter of 2025.

  • On a non-GAAP basis, operating profit was $86.5 million for the third quarter of 2026, compared to $50.8 million for the third quarter of 2025.

The company recorded net income of $37.9 million for the third quarter of 2026 compared to $12.9 million for third quarter of 2025.

  • On a non-GAAP basis, net income was $71.1 million for the third quarter of 2026, compared to $34.7 million for the third quarter of 2025.

During Q3 2026, the company generated positive cash flow. As a result, cash, cash equivalents, restricted cash and investments totaled $376.4 million on September 30, 2026.

The accompanying tables provide GAAP and non-GAAP financial information for the three and nine months ended September 30, 2026. Non-GAAP measures include adjustments, as applicable, for the sale of the European ORLADEYO business on October 1, 2025 (including transaction-related costs), stock-based compensation, expenses incurred in connection with the acquisition of Astria on January 23, 2026, employee termination and impairment charges related to the Birmingham site closure, and workforce reduction expenses. Management believes that the presentation of these non-GAAP figures provides greater transparency into the financial results of core, ongoing operations and improves comparability across reporting periods by excluding items that are non-recurring or other items that may vary significantly from period to period.

Financial Outlook for 2026

The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million and increased its full year 2026 total revenue outlook, including revenue from RAPIVAB® (peramivir injection) and the licensing of navenibart European rights, to $715 million to $730 million. The increase was primarily driven by higher revenues from the licensing of navenibart rights, as well as higher RAPIVAB orders from international partners.

The company improved its outlook for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to $415 million to $425 million. The decrease was primarily driven by continued progress on the Birmingham site closure.

| Item | As of November 4, 2026 | As of August 5, 2026 |

| ORLADEYO revenue | Unchanged | $625 million to $645 million |

| Total revenue | $715 million to $730 million | $690 million to $715 million |

| Non-GAAP operating expense | $415 million to $425 million | $420 million to $440 million |

Conference Call and Webcast

BioCryst management will host a conference call and webcast at 8:30 a.m. ET today to discuss the financial results and provide a corporate update. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Non-GAAP Financial Measures

The information furnished in this release and the accompanying tables includes non-GAAP financial measures that differ from measures calculated in accordance with generally accepted accounting principles in the United States of America (“GAAP”), including financial measures labeled as “non-GAAP.” As noted under “Third Quarter 2026 Financial Results” above, we believe providing these non-GAAP measures, which show our results with certain items adjusted, is valuable and useful since they can provide greater transparency into the financial results of core, ongoing operations and improve comparability across reporting periods. These non-GAAP measures also correspond with the way we expect investors and financial analysts to compare our results. Our non-GAAP measures should be considered only as supplements to, and not as substitutes for or in isolation from, our other measures of financial information prepared in accordance with GAAP. A reconciliation between each non-GAAP financial measure and its respective closest equivalent GAAP financial measure is provided in the tables below.

We also provide our non-GAAP operating expense outlook for full year 2026, which refers to our expected GAAP operating expense, excluding stock-based compensation, restructuring and transaction-related costs. We have not provided a reconciliation against the comparable forward-looking GAAP measure because we are unable to predict with reasonable certainty the full amount of stock-based compensation expense or restructuring or transaction-related costs for the full year 2026 without unreasonable effort. Stock-based compensation expense is uncertain and depends on various factors, including our future hiring and retention needs, as well as the future fair market value of our common stock, which is difficult to predict and subject to change. In addition, we are unable to predict with reasonable certainty the full amount of restructuring and transaction-related costs as the related costs are dependent on various factors that have not yet or have only recently occurred. The actual amount of stock-based compensation, restructuring and transaction-related costs for the full year 2026 could have a material impact on GAAP reported results for the guidance period.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements, such as expected full year 2026 revenue and operating expenses, expectations regarding pipeline development, including with respect to the timing of data and plans to report such data, accessibility of ORLADEYO for patients, expectations regarding BioCryst’s future growth and value creation, expectations related to the closure of BioCryst’s Birmingham research facility and wind-down of internal discovery programs, including statements about the expected timing, cost and anticipated related future cost savings, and expectations related to the CareMed transition, including future inventory levels and purchasing patterns. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully progress its pipeline development plans as described herein, including meeting the expected timelines; BioCryst’s ability to successfully transition to CareMed and to continue to successfully commercialize ORLADEYO, including the successful launch of the ORLADEYO oral pellet formulation; BioCryst’s ability to successfully execute its plan to close the Birmingham research facility and wind-down its internal discovery programs, including the timing and costs of such actions and its ability to realize the anticipated cost savings; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations, including that our partners may fail to reach performance milestones or achieve certain royalty thresholds under our license agreements; statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and BioCryst’s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management’s expected ranges. This list is not exclusive. To see a more comprehensive list of risks, please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

BioCryst to Present at Upcoming Investor Conferences Bull 0 Bear 0 Routine

November 4, 2026

PDF Version

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

  • 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 8:30 a.m. ET.

  • 9th Annual Evercore Healthcare Conference in Coral Gables, FL, on Tuesday, December 1, 2026, at 8:45 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

October 29, 2026

PDF Version

—New data highlight BioCryst's commitment to advancing a portfolio of therapies for people living with HAE—

RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that four abstracts from its hereditary angioedema (HAE) portfolio have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting taking place in Phoenix, Arizona, November 12-16.

BioCryst will present new clinical data and real-world outcomes for ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring long-term clinical trial outcomes for navenibart, a long-acting injectable monoclonal antibody plasma kallikrein inhibitor being investigated for prophylaxis to prevent attacks of HAE.

BioCryst will present the following four posters​ at the Phoenix Convention Center:

  • **Hospitalization and Emergency Department Reductions After Initiating Berotralstat, Lanadelumab, or Subcutaneous Plasma-Derived C1-Inhibitor for Hereditary Angioedema;**Poster #R077; Monitor 17; Friday, November 13, 4:20-4:35 p.m. MT

  • **Reductions in Healthcare Utilization Among Individuals with HAE Who Switched to Berotralstat from Another Prophylaxis;**Poster #R096; Monitor 15; Saturday, November 14, 11:30-11:45 a.m. MT

  • **Growth-Related Berotralstat Dose Adjustment in Children with Hereditary Angioedema: 48-Week Dosing Experience from APeX-P;**Poster #R097; Monitor 15; Saturday, November 14, 11:45 a.m.-12:00 p.m. MT

  • **Long-Term Safety, Efficacy, and Quality of Life with Navenibart in Hereditary Angioedema: ALPHA-SOLAR Interim Results;**Poster #R110; Monitor 13; Sunday, November 15, 12:00-12:15 p.m. MT

In addition to the presentation times noted above, posters will be accessible to registered attendees during the ACAAI 2026 Annual Scientific Meeting.

Visit www.ORLADEYO.com for more information.

About ORLADEYO**®****(berotralstat)** ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older. One dose of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

About navenibart Navenibart is an investigational YTE-modified monoclonal antibody inhibitor of plasma kallikrein, an established and safe mechanism, currently being evaluated in clinical trials for long-term prevention of HAE attacks with potential best-in-class dosing every 3 or 6 months.

U.S. Indication and Important Safety Information

INDICATION ORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.

Limitations of use The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or doses of ORLADEYO higher than the prescribed once-daily dose are not recommended due to the potential for QTc interval prolongation.

IMPORTANT SAFETY INFORMATION An increase in QTc interval was observed in adults at dosages higher than 150 mg once daily and was concentration dependent.

The most common adverse reactions (≥10%) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

In adult and pediatric patients aged 12 years and older with moderate or severe hepatic impairment (Child-Pugh B or C), the recommended dosage of ORLADEYO capsules is 110 mg once daily with food. In pediatric patients aged 2 to <12 years with moderate or severe hepatic impairment (Child-Pugh B or C), avoid use of ORLADEYO.

Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein. P-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. Avoid concomitant use of P-gp inducers with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. Concomitant use of ORLADEYO with CYP2D6 or CYP3A4 substrates can increase exposure of the CYP2D6 or CYP3A4 substrates and may increase the risk of adverse reactions associated with the substrates. If ORLADEYO is concomitantly used with CYP2D6 or CYP3A4 substrates where minimal increases in the concentration of the substrates may lead to serious adverse reactions, closely monitor or modify the dosage of the CYP2D6 or CYP3A4 substrate.

The safety and effectiveness of ORLADEYO in pediatric patients <2 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Forward-Looking Statements This press release contains forward-looking statements, including statements regarding BioCryst’s expectations relating to its HAE portfolio and the development, potential dosing profile, competitive positioning, and expectations for navenibart. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst’s ability to successfully progress its development plans for navenibart; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; ongoing and future clinical development of product candidates, including navenibart, may take longer than expected and may not have positive results; BioCryst may not advance human clinical trials with product candidates, including navenibart, as expected; the FDA or other applicable regulatory agencies may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates, may ultimately determine that there are deficiencies in the development program or execution thereof, may require additional information or studies, may disagree with our safety and efficacy conclusions, or may impose certain restrictions, warnings, or other requirements; product candidates, if approved, may not achieve market acceptance; and BioCryst’s ability to successfully commercialize its products and product candidates. This list is not exclusive. To see a more comprehensive set of risks, please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s forward-looking statements.

BCRXW

Prompts

BioCryst Pharmaceuticals, Inc. (ticker BCRX), listed in United States.

ETFs Holding BioCryst Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
JSMD 0.92% 1,078,429 $ 9.684M Jul 31, 2026
JSML 0.62% 248,560 $ 2.232M Jul 31, 2026
LITL 0.48% 3,635 $ 27.263K Nov 17, 2026
IVSS 0.21% 5,666 $ 56.66K Jun 30, 2026
PSC 0.19% 445,890 $ 4.459M Jun 30, 2026
FSEG 0.15% 876 $ 8,760.00 Jun 30, 2026
ESSC 0.14% 5,593 $ 50.225K Jul 31, 2026
SCDS 0.12% 1,438 $ 10.785K Nov 17, 2026
FESM 0.12% 693,212 $ 6.932M Jun 30, 2026
RESM 0.07% 251 $ 2,510.00 Jun 30, 2026
MSSM 0.01% 8,960 $ 86.912K Aug 31, 2026
DFAC 0.00% 36,571 $ 280.865K Nov 12, 2026
DCOR 0.00% 286 $ 2,196.48 Nov 12, 2026
AVUQ 0.00% 1,257 $ 9,364.65 Nov 16, 2026